Drugs for treating infections caused by non-tubercular mycobacteria: A narrative review from the study group on mycobacteria of the Italian Society of Infectious …

A Calcagno, N Coppola, L Sarmati, M Tadolini… - Infection, 2024 - Springer
Background Non-tuberculous mycobacteria (NTM) are generally free-living organism, widely
distributed in the environment, with sporadic potential to infect. In recent years, there has …

In vitro activity of omadacycline against clinical isolates of Nocardia

J Pham, RJ Benefield, N Baker… - Antimicrobial Agents …, 2024 - journals.asm.org
Nocardiosis typically requires a prolonged treatment duration of≥ 6 months and initial
combination therapy with 2–3 antibiotics. First-line regimens for nocardiosis are associated …

Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation

GD Boorgula, T Gumbo, S Singh, PJ McShane… - Tuberculosis, 2024 - Elsevier
Background Drug susceptibility testing (DST) protocol of omadacycline against non-
tuberculous mycobacteria has not yet been established. We developed a method to …

Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model

S Singh, T Gumbo, GD Boorgula… - Antimicrobial Agents …, 2024 - journals.asm.org
Seventy-five years ago, first-generation tetracyclines demonstrated limited efficacy in the
treatment of tuberculosis but were more toxic than efficacious. We performed a series of …

Sarecycline pharmacokinetics/pharmacodynamics in the hollow-fibre model of Mycobacterium avium complex: so near and yet so far

S Singh, GD Boorgula, S Aryal… - Journal of …, 2024 - academic.oup.com
Background Poor sustained sputum culture conversion rates with the standard-of-care
therapy highlight the need for better drugs to treat Mycobacterium avium complex pulmonary …

An auxiliary strategy of partial least squares regression in pharmacokinetic/pharmacodynamic studies: A case of application of guhong injection in myocardial …

H Chen, C Li, C Shao, Y Wu, H Wan… - Journal of Food and …, 2023 - pmc.ncbi.nlm.nih.gov
Guhong injection (GHI) has been applied in the therapy of cardio-cerebrovascular disease
in clinic, but there is no report about the pharmacokinetic/pharmacodynamic (PK/PD) …

Isoniazid pharmacokinetics/pharmacodynamics as monotherapy and in combination regimen in the hollow fiber system model of Mycobacterium kansasii

GD Boorgula, S Singh, P Shankar, T Gumbo… - Tuberculosis, 2023 - Elsevier
Background There is limited high quality evidence to guide the optimal doses of drugs for
the treatment of Mycobacterium kansasii pulmonary disease (Mkn-PD). Methods We …

Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy

D Deshpande, S Srivastava, JG Pasipanodya… - Frontiers in …, 2022 - frontiersin.org
Background: There is need for shorter duration regimens for the treatment of tuberculosis,
that can treat patients regardless of multidrug resistance status (pan-tuberculosis). Methods …